Yes, I would think so and I believe it’s happened before with other Enhanze products. I guess the devil is always in the details. I just read that ocrevus is administered only twice a year and it takes about 4 hours each time including premedication, etc. It looks like a minimum of 22 weeks will be kept between SC doses so probably the goal is to have two a year as well. It feels like uncharted territory and I would be very curious to know what Roche, Halo and analysts think the conversion rate to the SC formulation will be if all goes well and it gets approved.
News 
Market Data 
Discover 
AI
